Hepatitis D Market Insights, Epidemiology & Forecast - 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Hepatitis D - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

The global market of Hepatitis D was estimated to be USD 656 Million in 2016, and is expected to increase from 2016-2027.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hepatitis D in the United States, EU5, Japan and China.

The Hepatitis D epidemiology division provide the insights about historical and current patient pool and forecasted trend for each of the 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalence by Severity, Gender Specific prevalence, Age Specific prevalence and diagnosed cases] of Hepatitis-D in the 8MM covering United States, EU5 countries, Japan and China from 2016-2027.

This segment of Hepatitis D report encloses the detailed analysis of marketed drugs and late stage pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The Hepatitis D market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Companies Mentioned

  • Hoffmann-La Roche
  • Replicor Inc.
  • MYR Pharma
  • Eiger BioPharmaceuticals

Key Topics Covered:

1. Key Insights

2. Hepatitis D Market Overview at a Glance

3. Disease Background and Overview: Hepatitis D

4. Epidemiology and Patient Population

5. Country Wise-Epidemiology of Hepatitis D

6. Current Treatment Practices

7. Treatment Algorithm

8. Unmet needs

9. Emerging Therapies

10. Hepatitis D: Market Analysis

11. Key Findings

12. Market Size of Hepatitis D by Country

13. Market Drivers of Hepatitis D

14. Market Barriers of Hepatitis D

15. Appendix

16. Report Methodology

17. Capabilities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/crfcj9/hepatitis_d?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Liver and Kidney Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Liver and Kidney Disorders Drugs